Immunome Inc. Debt-to-equity in % from Q2 2021 to Q3 2025

Taxonomy & unit
ratio: %
Description
Debt-to-equity (D/E) ratio is used to evaluate a company's financial leverage and is calculated by dividing a company's total liabilities by its shareholder equity.
Summary
Immunome Inc. quarterly Debt-to-equity history and growth rate from Q2 2021 to Q3 2025.
  • Immunome Inc. Debt-to-equity for the quarter ending September 30, 2025 was 15.4 %, a 8.67% decline year-over-year.
Debt-to-equity, Quarterly (%)
Debt-to-equity, YoY Quarterly Growth (%)

Immunome Inc. Quarterly Debt-to-equity (%)

Period Value YoY Chg Change % Date
Q3 2025 15.4 -1.46 -8.67% Sep 30, 2025
Q2 2025 16.8 -12.1 -41.8% Jun 30, 2025
Q1 2025 18.7 -24.5 -56.7% Mar 31, 2025
Q4 2024 19 -103 -84.4% Dec 31, 2024
Q3 2024 16.8 -333 -95.2% Sep 30, 2024
Q2 2024 28.9 -100 -77.6% Jun 30, 2024
Q1 2024 43.3 -25.7 -37.3% Mar 31, 2024
Q4 2023 122 +91.1 +294% Dec 31, 2023
Q3 2023 350 +324 +1264% Sep 30, 2023
Q2 2023 129 +108 +512% Jun 30, 2023
Q1 2023 69 +53.6 +350% Mar 31, 2023
Q4 2022 31 +18.2 +143% Dec 31, 2022
Q3 2022 25.7 +15.8 +161% Sep 30, 2022
Q2 2022 21.1 -5.47 -20.6% Jun 30, 2022
Q1 2022 15.3 Mar 31, 2022
Q4 2021 12.8 Dec 31, 2021
Q3 2021 9.85 Sep 30, 2021
Q2 2021 26.6 Jun 30, 2021
* An asterisk sign (*) next to the value indicates that the value is likely invalid.